Introduction
Matrix metalloproteinases (MMPs) belong to a family of zinccontaining extracellular endopeptidases that selectively degrade components of the extracellular matrix, such as proteoglycans, laminin, and fibronectin. Currently, 19 members have been identified in the human MMP family. Under normal conditions, the activities of MMPs seem to be balanced by tissue inhibitors of metalloproteinases (TIMPs). It has been shown that MMPs, as well as TIMPs, are key players in many physiological and pathological processes such as development, angiogenesis, connective tissue remodeling, wound healing, immunity, and inflammation. [1] [2] [3] In cancer patients, MMPs also play an important role in disease progression and their activities are reported to associate with tumor promotion, 4 angiogenesis, 5 invasion, and metastasis. 6 Much of the work on the role of MMP inhibitors has concentrated on their inhibitory effects in tumor invasion models, both in vivo and in vitro. 7, 8 Synthetic MMP inhibitors, such as BB-2516 (marimastat), have been designed for clinical application to inhibit metastasis. 9 Since MMP inhibitors alone do not induce cell death in most cancer cells in vitro, they are often used in the stabilization of tumor growth in cancer patients, thus improving survival. 6 Dysregulated production of MMPs and TIMPs has been reported in hematopoietic malignancies.
The abnormal MMP/TIMP expression in hematopoietic malignancies may indicate the premature egress of leukemic blasts from bone marrow and their dissemination into peripheral tissues. Consequently, MMP inhibitors should be candidates for agents in the treatment of hematopoietic malignancies.
To date, most patients with acute myeloid leukemia achieve complete remission with cytotoxic chemotherapy, but, due to recurrence, long-term survival is limited. Anti-cancer drugs act to induce apoptosis in cancer cells. However, they also activate some anti-apoptotic pathways in cancer cells, such as NF-B, thus blocking apoptosis.
11 This is at least one reason for the inefficient elimination of leukemia cells by anti-cancer drugs, leading to recurrence. Therefore, new drugs that cause apoptosis without activating the survival signal pathway are required.
Naito
Institute, Ibaragi, Japan), a new inhibitor of MMPs, from microbial cultures. This MMP inhibitor has been shown to effectively suppress growth of human fibrosarcoma HT1080 cells in an in vivo nude mouse model. From BE16627B, we synthesized a new MMP inhibitor, SI-27, that demonstrates significantly greater MMP-inhibiting activity. This MMP inhibitor suppresses the growth of human fibrosarcoma HT1080 cells in vivo more efficiently than BE16627B (unpublished observation). The structure of SI-27 is shown in Figure 1 .
In the present study, we investigated the effects of the new MMP inhibitor, SI-27. SI-27 alone activates some caspases and induces apoptosis in several human myeloid leukemia cell lines. Furthermore, at lower concentrations that do not directly induce apoptosis, SI-27 acts to sensitize U937 cells and other cells to tumor necrosis factor ␣ (TNF-␣)-mediated apoptosis. It is most likely that this sensitization is mediated by blocking NF-B activation through the cleavage of IB␣.
Figure 1
The molecular structure of SI-27.
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Materials and methods
Enzymes and MMP assays
MMP activity was measured as previously reported. 12 One unit of MMP activity was defined as that causing 1 g of degraded substrate to become soluble in trichloroacetic acid in 1 min at 37°C. All enzymatic assays were carried out in 50 mM Tris-HCl buffer (pH 7.5) containing 10 mM CaCl 2 13 
Cell lines and culture
The human cell lines U937, HL-60, NB-4, and THP-1 (provided from Saitama Cancer Center Research Institute, Japan) were maintained in culture in RPMI 1640 supplemented with 10% fetal bovine serum (FBS; GIBCO-BRL, Grand Island, NY, USA), 100 unit/ml penicillin G and 100 g/ml streptomycin. SI-27 was dissolved in dimethylsulfoxide (DMSO) to produce a 20 mM stock solution. Cell lines (5 × 10 4 /ml) were treated with a vehicle (DMSO) or several concentrations of SI-27 for 24 h. 100 M and 200 M SI-27 contained 1% DMSO while all others contained 0.1% DMSO. At the end of treatment, surviving cells were identified by a WST-1 (Wako Pure Chemicals Industries, Osaka, Japan) assay, with the untreated controls acting as a 100% reference. The WST-1 assay was performed to measure the growth of cells with SI-27 according to the manufacturer's instructions.
Determination of apoptotic cell death
The leakage of fragmented DNA from apoptotic nuclei was measured by the method of Nicoletti et al. 14 Briefly, cells were prepared in a lysis buffer (phosphate-buffered saline (PBS), 0.2% Triton X-100, 50 g/ml propidium iodide (PI)) and then subjected to FACS analysis to quantify the population in the sub-G1 region. Phosphatidylserine (PS) externalization was measured by staining with FITC-conjugated annexin V (Trevigen, Gaithersburg, MD, USA) according to the manufacturer's protocol. A drop in mitochondrial transmembrane potential (⌬⌿m) was measured by staining with CMX-Ros (Molecular Probes, Eugene, OR, USA) as previously described. 15 We used intact cells (not fixed cells) and analyzed them immediately to measure ⌬⌿m via flow cytometry. All flow cytometry analyses were performed on a FACScalibur using CellQuest analysis software (Becton Dickinson, San Jose, CA, USA).
The broad range caspase inhibitors zVAD-fmk and Z-Asp-CH2-DCB, as well as specific caspase inhibitors Ac-DEVD-CHO, Ac-IETD-CHO, Ac-YVAD-CHO, and Ac-LEHD-CHO were purchased from the Peptide Institute (Osaka, Japan). Caspase inhibitors were added 30 min before SI-27 treatment. After 24 h, apoptosis was analyzed by flow cytometry. Tumor necrosis factor-␣ (TNF-␣) was purchased from Boehringer Mannheim Biochemica (Mannheim, Germany).
Western blots
/ml of U937 cells were treated with 200 M SI-27. Cells were then harvested and lysed in an SDS sample buffer (0.04 M Tris-HCl (pH 6.8), 2% SDS, 5% 2-mercaptoethanol, 5% glycerol, and 0.5% BPB) and boiled for 5 min. An aliquot of the lysate (2 × 10 5 cells) was then analyzed by Western blotting. Proteins were resolved by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and electroblotted on to polyvinylidene difluoride membranes. Membranes were blocked for 1 h with 5% non-fat dry milk powder in Tris-buffered saline (TBS: 10 mmol/l, Tris-HCl pH 7.4, 100 mmol/l NaCl) with 0.05% Tween20 (TBST) and then immunoblotted for 1 h with several antibodies. Antibodies were purchased from the following suppliers: against caspase 3 and caspase 2 (Transduction Laboratories, Lexington, KY, USA), against caspase 8 were (Immnotech, Marseille, France), against caspase 9 (Millennium Biotechnology, Ramona, CA, USA), against Bcl-2, Bcl-X L , Bax, and IB␣ (Santa Cruz Biotechnology, Santa Cruz, CA, USA), against PARP (Pharmingen, San Diego, CA, USA), and against Actin (Boehringer Mannheim Biochemica). Membranes were washed three times with TBST and incubated with peroxidaseconjugated affinity-purified rabbit anti-mouse or goat anti-rabbit IgG for 1 h. After extensive washing, the reactions were developed by enhanced chemiluminescent staining (DuPont NEN, Boston, MA, USA). Anti-actin antibody staining confirmed the loading and transfer of equal amounts of protein.
Flow cytometric analysis of Fas, the Fas ligand, and TNF receptor 1 membrane expression
U937 cells were treated with 20 or 200 M SI-27 for 24 h. Fas, the Fas ligand, and TNF receptor 1 expression were measured by flow cytometry by incubating cells for 30 min at 4°C with mouse anti-Fas (ZB4), hamster anti-Fas ligand (4A5) (MBL, Nagoya, Japan), and mouse anti-TNF receptor 1 (Dako, Glostrup, Denmark) antibodies. After two washes in PBS, cells were incubated for 30 min at 4°C with a fluorescein isothiocyanate-labeled rabbit anti-mouse IgG (Dako) or rabbit antihamster IgG (Cappel, Aurora, OH, USA) and analyzed with FACScalibur.
Fas and the Fas ligand blocking assay
For the blocking assay, U937 cells were incubated for 1 h with 10 g/ml antagonistic anti-Fas (ZB4) or anti-Fas ligand (4A5) antibodies before 200 M SI-27 treatment. Then, 24 h later, apoptosis was determined as described above.
Results
Inhibition of MMPs by SI-27
Like BE16627B, 12 SI-27 inhibits metalloproteinases, such as MMP-2, MMP-3, MMP-9, thermolysin, bacterial collagenase, and leucine aminopeptidase. Its IC 50 values for these enzymes are shown in Table 1 . SI-27 did not inhibit any other proteinase tested, including trypsin, chymotrypsin, papain, pepsin, and elastase. 
SI-27 induces apoptosis in several myeloid leukemia cell lines
We examined the effect of SI-27 on the survival of several hematopoietic cell lines. A WST-1 assay revealed that SI-27 had a dose-dependent suppressive effect on the growth of some of leukemia cell lines such as U937, NB-4, and HL-60, cells, but not THP-1 cells (Figure 2 ). Normal peripheral bloodderived mononuclear cells (PBMCs) were used as a normal control for the WST-1 assay in Figure 2 . After 24 h of culture in RPMI1640 containing 10% FBS with or without 1% DMSO, 70% or 80% of PBMCs survived, respectively. The survival rate of PBMCs treated with 200 M SI-27 was 70%, and comparable with that of 1% DMSO treatment (data not shown).
In addition to the data in Figure 2 , these data suggest that SI- Leukemia 27 treatment inhibits the growth of (at least some types of) leukemia cells but does not affect that of normal hematopoietic cells.
Interestingly, SI-27-treated U937 cells displayed morphological signs of apoptosis including cell shrinkage, membrane blebbing, and eventual disintegration into numerous apoptotic bodies within 12 h of treatment (data not shown). These observations suggest SI-27 can induce apoptosis in some leukemia cell lines. To test this hypothesis, we analyzed apoptosis in a number of ways, including ⌬⌿m loss by CMX-Ros staining, phosphatidylserine (PS) externalization by annexin V binding, and the presence of hypodiploid DNA in U937 cells before and after SI-27 treatment. U937 cells, after 24 h treatment with 200 M SI-27, showed low ⌬⌿m and DNA fragmentation, and were annexin V-positive, which typically indicates apoptosis, much more than those receiving DMSO treatment alone (Figure 3) .
SI-27 induces some caspases' activation, but does not affect the protein levels of Bcl-2, Bcl-X L , Bad and BAX
To elucidate the molecular basis for SI-27-induced apoptosis, we examined the activation of caspases. Appropriate cleavage of procaspase is necessary for the activation of caspase enzymes. Figure 4a indicates that SI-27 treatment induced the cleavage of initiator procaspase 8 and 9, and effector procaspase 3, but not procaspase 2. To determine whether cleaved procaspase becomes active, we analyzed the cleavage of various caspase substrates. Figure 4b indicates that SI-27 treatment induced the cleavage of PARP and IB␣ both substrates for caspase 3. In contrast with caspases, the levels of Bcl-2 family proteins, anti-apoptotic Bcl-2, and Bcl-X L , and pro- apoptotic BAD and BAX did not change during SI-27 treatment.
Pancaspase inhibitors block SI-27-induced apoptosis, but not by specific caspase inhibitors
To further demonstrate the activation of caspases during SI-27-induced apoptosis, the effect of pancaspase inhibitors, as well as specific caspase inhibitors, on apoptosis was examined. Several caspase inhibitors were added 30 min before SI-27 treatment, and then apoptosis was analyzed by flow cytometry. The pancaspase inhibitors zVAD-fmk and Z-Asp-CH2-DCB efficiently blocked SI-27-induced apoptosis, but specific caspase inhibitors for caspase 1 (Ac-YVAD-CHO), 8 (Ac-IETD-CHO), 3 (Ac-DEVD-CHO), and 9 (Ac-LEHD-CHO, data not shown), did not. Loss of ⌬⌿m was only partially recovered, while hypodiploid DNA was completely recovered by the addition of the pancaspase inhibitor zVAD-fmk or Z-Asp-CH2-DCB ( Figure 5 ). The cleavage of PARP and IB␣ by SI-27 were also blocked by the pancaspase inhibitors, zVADfmk and Z-Asp-CH2-DCB, but were not blocked by specific caspase inhibitors (data not shown).
SI-27 sensitizes U937 cells to apoptosis induced by TNF-␣
The effectiveness of cancer therapy is determined by its ability to trigger apoptosis in malignant cells and its toxicity profile.
TNF-␣ activates not only death signals, but also survival signals that are mediated by the activation of NF-B transcription factors, leading to limitations in TNF-␣ cancer therapy. However, blocking NF-B activation has been reported to induce apoptosis by TNF-␣. 16 As shown in Figure 4b , 200 M of SI-27 cleaves IB␣. It has been suggested that cleaved IB␣ may become a super-repressor form of IB␣. It may block the activation of NF-B, 17 thus improving the cancer fighting abilities of TNF-␣. We therefore investigated whether TNF-␣-induced apoptosis was augmented by SI-27. We found that 20 M SI-27, which cannot cleave IB␣ nor activate caspases, nor directly induce apoptosis on U937 cells, markedly enhanced the cytotoxicity of TNF-␣ compared to DMSO-treated controls ( Figure 6 ).
SI-27 sensitized HL-60, NB4, as well as U937 cells but not THP-1 cells to TNF-␣ (data not shown). As expected, TNF-␣ in the presence of 20 M SI-27 induced cleavage of IB␣ in U937 cells but TNF-␣ with DMSO alone did not (data not shown).
SI-27 does not affect the expression of membrane Fas, the Fas ligand or TNF receptor 1 on U937 cells
Since MMP inhibitors block the shedding of several receptors and ligands, including the TNF-␣ receptor (TNFR), one of the mechanisms by which SI-27 causes increased sensitization to the cytotoxic action of TNF-␣ may be via the up-regulation of TNFR. 18 To clarify this, we measured the expression of TNFR on the surface of U937 cells, but found that 20 M or 200 (Figure 7) . Furthermore, 10 g/ml of antagonistic Fas and the Fas ligand antibodies did not block SI-27-induced apoptosis (Figure 8 ).
Discussion
Synthetic MMP inhibitors, such as BB-2516 (marimastat) have been designed for use in clinical applications to inhibit metastasis in cancer patients. Also, the low molecular weight broad-spectrum MMP inhibitor BE16627B suppresses primary subcutaneous tumor growth, as well as lung colonization of human fibrosarcoma cells, in nude mice with no apparent cytotoxicity. 12 Another hydroxamic acid-based MMP inhibitor, KB-R7785, also prevented angiogenesis and metastasis of C26 murine adenocarcinoma in an in vivo mouse model. 20 In the present study, we demonstrated that a new synthetic
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Figure 5
The effects of caspase inhibitors on SI-27-induced apoptosis. After treatment with 200 M of SI-27 alone or with 200 M of SI-27 and 100 M of various caspase inhibitors for 24 h, apoptosis was analyzed by flow cytometry. Untreated cells were used as a control. The apoptosis of untreated cells was almost the same as that in MMP inhibitor, SI-27, showed a direct apoptosis-inducing effect on several leukemia cell lines. SI-27 exposure induced a variety of changes in pro-apoptotic proteins including caspases. Apoptosis was documented by annexin V-positive staining, a drop in ⌬⌿m, the presence of hypodiploid DNA, and cleavage of PARP and IB␣. These effects do not appear to be the result of non-specific toxicity, as SI-27 does not induce apoptosis in THP-1 cells or other hematopoietic cell lines, such as Jurkat, and KG-1 (data not shown).
Several recent studies have shown that some metalloproteinases mediate TNF-␣ and Fas ligand processing, and that metalloproteinase inhibitors could block the shedding of the Fas ligand. 19 As U937 cells express the membrane-type Fas ligand and Fas receptor, and because TNF-␣ up-regulates the membrane-type Fas ligand (unpublished observation), we investigated whether SI-27 treatment increased the expression of membrane-type Fas ligand or Fas receptor. However, SI-27-treated U937 cells showed neither membrane Fas ligand accumulation nor protection from apoptosis with anti-Fas and anti-Fas ligand neutralizing antibodies. These data suggest that SI-27-induced apoptosis is independent of the Fas pathway activated by the increased expression of Fas receptor and Fas ligand on U937 cells. Recently, Mitsiades et al 21 reported that two MMP inhibitors, BB-3103 and A151011, induced apoptosis in a Fas-sensitive cell line, which could then be blocked by Fas-neutralizing antibodies. However, these results could vary with different cell lines and MMP inhibitors used. Similarly, Fas and the Fas ligand pathway have been reported to mediate anti-cancer drug-induced apoptosis, but this type of apoptosis was dependent on the cell type examined. [22] [23] [24] Therefore, it may be that MMP inhibitors behave in a comparable manner, suggesting that results may be cell line-dependent.
BE16627B, a hydroxamic acid-based MMP inhibitor, does not induce apoptosis and does not sensitize to TNF-␣ in U937 cells (data not shown). On the basis of its structure, SI-27, but not BE16627B, is believed to be cell permeable. For instance, the aminopeptidase inhibitor ubenimix-methyl-ester is more cell permeable than ubenimix and the former induces apoptosis more efficiently than the latter. 25 Therefore, like ubenimix, accessible targets of SI-27 may be intracellular metalloproteinases or other types of proteinases, and SI-27 may induce apoptosis by blocking them. The precise mechanism of its action currently remains unknown and further investigation is needed.
There are two conflicting pathways downstream of TNFR; one leads to apoptosis mediated by caspases and another activates the survival signaling pathway mediated by NF-B, which is anti-apoptotic. 16 Inhibition of NF-B activation by a non-inducible form of IB␣ renders cells more susceptible to TNF-␣-induced apoptosis. Caspase 3 is known to cleave IB␣ in vitro. 17 Once cleaved, IB␣ loses the C-terminal region responsible for degradation, and becomes a super-repressor form of IB␣ thus blocking NF-B activation. If IB␣ cleaved by SI-27 is converted to the super-repressor form, SI-27-cleaved IB␣ also blocks NF-B activation, and sensitizes cells to apoptosis by TNF-␣.
What determines the sensitivity of the cells to SI-27 treatment remains unknown. If IB␣ cleaved by SI-27 blocks the activation of the NF-B pathway, the cell lines in which survival mainly depends on the NF-B pathway are sensitive to SI-27. Chemotherapy has been highly effective in inducing complete remission in acute myelogenous leukemia. 26 Unfortunately, despite intensive chemotherapy, the vast majority of patients continue to relapse and succumb to the disease. Therefore, new drugs with alternative mechanisms of action, such as NF-B blockers, need to be developed for use, alone or in combination with chemotherapy, to treat this disease. Our findings suggest the possibility that MMP inhibitors can provide a unique method of treatment for hematopoietic malignancies refractory to classical anti-cancer drugs, and further that MMP inhibitors alone or in combination with other cytotoxic agents may suppress recurrence of disease. The search for anti-cancer drugs with synergistic effects with SI-27 may prove to be highly beneficial in the fight against hematopoietic malignancies.
